AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer

Application based on results from the TROPION-Breast01 Phase III trial

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis

Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations

NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer

If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy

EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results

Apollo Cancer Centres heralds a new era in breast cancer surgery

The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer

Combination shows consistent benefit across prespecified post-progression outcomes

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer

Dr. Reddy's Laboratories launches Versavo in the UK

Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK